Goodwin Procter recently advised ProQR Therapeutics, a biopharmaceutical company, on its initial public offering of 8,625,000 ordinary shares. Shares priced at $13.00 per share and are traded on the Nasdaq Global Market under ticker symbol “PRQR.” Net proceeds from the offering are approximately $102 million.
Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering. JMP Securities acted as lead manager, and H.C. Wainwright & Co., LLC acted as co-manager for the offering.
ProQR Therapeutics, based in the Netherlands, is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders. The company was founded in 2012 with the initial goal of developing a treatment for cystic fibrosis.
The Goodwin team advising ProQR was led by partners Mitchell Bloom and Danielle Lauzon, and included associate James Xu (corporate), partner Duncan Greenhalgh and associate Jeffrey Kessler (IP), partner Janet Andolina (tax), and partner Ettore Santucci (Opinions). Associate Sarah Bock (Benefits), and partner Jennifer Chunias (FCPA) provided additional support.
More information about the offering can be found in the company’s closing press release.